InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972 3 6917691
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
InspireMD (NASDAQ:NSPR) Frequently Asked Questions
What is InspireMD's stock symbol?
InspireMD trades on the NASDAQ under the ticker symbol "NSPR."
When is InspireMD's next earnings date?
What is the consensus analysts' recommendation for InspireMD?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InspireMD.
Has InspireMD been receiving favorable news coverage?
Media coverage about NSPR stock has been trending positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. InspireMD earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for InspireMD.
Who are some of InspireMD's key competitors?
Some companies that are related to InspireMD include Myomo (MYO), Myomo (MYO), Micron Solutions (MICR), Adherium (ADR), Cannabix Technologies (BLOZF), Cannabix Technologies (BLO), COCHLEAR LTD/ADR (CHEOY), Ellex Medical Lasers (ELXMF), GN Store Nord A/S (GGNDF), Neuroone Medical Technologies (NMTC), Ortho Regenerative Technologies (ORTH), PetVivo (PETV), Quadron Cannatech (QCC), Rafina Innovations (VICA) and Sartorius Stedim Biotech (DIM).
What other stocks do shareholders of InspireMD own?
Who are InspireMD's key executives?
InspireMD's management team includes the folowing people:
- Dr. James J. Barry, Pres, CEO & Director (Age 60)
- Mr. Craig Shore, CFO, Chief Admin. Officer, Sec. & Treasurer (Age 58)
- Mr. Agustin V. Gago, Exec. VP & Chief Commercial Officer (Age 59)
- Mr. Benzi Spector, Head of R&D and Operations
- Dr. Sol J. Barer, Special Advisor to the Board (Age 72)
How do I buy shares of InspireMD?
Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InspireMD's stock price today?
One share of NSPR stock can currently be purchased for approximately $2.88.
How big of a company is InspireMD?
What is InspireMD's official website?
How can I contact InspireMD?
The company can be reached via phone at 972 3 6917691.
MarketBeat Community Rating for InspireMD (NASDAQ NSPR)
MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote "Outperform" if you believe NSPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
